軽度から中等度の乾癬のための外用SGX302
軽度から中等度の乾癬の治療における SGX302 (合成ヒペリシン) を評価する第 2 相試験
To evaluate SGX302 (topical hypericin ointment and gel) with visible light in an initial 18-week treatment course for improving lesions in patients with mild-to-moderate psoriasis.
調査の概要
研究の種類
入学 (実際)
段階
- フェーズ2
連絡先と場所
研究場所
-
-
California
-
San Diego、California、アメリカ、92123
- Therapeutics Clinical Research
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
- Have a clinical diagnosis of plaque psoriasis (psoriasis vulgaris) of at least 6-months duration that involves the body (trunk and/or limbs) that is amenable to topical treatment and opaque coverage after application.
- Have a static Investigator Global Assessment (IGA)/Psoriasis Area and Severity Index (PASI) of disease severity of mild or moderate on the body (trunk and/or limbs).
- Have lesions involving 2-30% of the body (trunk and/or limbs). For subjects with scalp psoriasis included in the treatment area, the total treatment area on body and scalp must not exceed 30%.
Exclusion Criteria:
- Use of topical anti psoriatic therapy within one week prior to the beginning of the study and willing to not use other psoriasis treatments for 4 weeks following completion of the treatment portion of the study.
- Received systemic biologic therapy to treat psoriasis within 12 weeks prior to the beginning of the study.
- Received systemic psoriasis therapy within 4 weeks prior to the beginning of the study.
- Received phototherapy (including laser) or photodynamic (light activated drug) therapy within 4 weeks prior to the beginning of the study.
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:処理
- 割り当て:ランダム化
- 介入モデル:順次割り当て
- マスキング:4倍
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
実験的:Cohort 1 - SGX302 Ointment (0.25 % Hypericin)
SGX302 (0.25 % hypericin) ointment will be applied to lesions and treated with visible light 24±6 hours later starting at 5 J/cm^2 with a gradual escalation of light therapy up to 25 J/cm^2. Drug application/light session will be done twice a week (at least 2 calendar days apart) for 18 weeks. |
SGX302 is synthetic hypericin formulated as a 0.25% hypericin ointment or gel.
他の名前:
|
|
実験的:Cohort 2 - SGX302 Ointment (0.25 % Hypericin)
SGX302 (0.25 % hypericin) ointment will be applied to lesions and treated with visible light 24±6 hours later starting at 5 J/cm^2 with a faster escalation of light therapy up to 25 J/cm^2. Drug application/light session will be done twice a week (at least 2 calendar days apart) for 18 weeks. |
SGX302 is synthetic hypericin formulated as a 0.25% hypericin ointment or gel.
他の名前:
|
|
実験的:Cohort 3 - SGX302 Gel (0.25 % Hypericin)
SGX302 (0.25 % hypericin) gel will be applied to lesions and treated with visible light 24±6 hours later starting at 5 J/cm^2 with a faster escalation of light therapy up to 40 J/cm^2. Drug application/light session will be done twice a week (at least 2 calendar days apart) for 18 weeks. |
SGX302 is synthetic hypericin formulated as a 0.25% hypericin ointment or gel.
他の名前:
|
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Number of Patients That Achieve a 0 or 1 Score Using the 5-point Investigator's Global Assessment Scale
時間枠:18 weeks
|
The percentage of patients in each treatment group that achieve a 0 or 1 score (Clear or Almost Clear) evaluation using the 5-point Investigator's Global Assessment (IGA) scale. The 5-point IGA scale:
|
18 weeks
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
SkinDex-29 Score
時間枠:Baseline, End of Treatment (Week 18)
|
The SkinDex-29 is a validated quality of life questionnaire that measures the effects of skin diseases on a person's life. It is a series of 30 questions assessing the participant's opinion of the impact of their disease on their life in the previous 4 weeks. Answers are scored from 1 (never), 2 (rarely), 3 (sometimes), 4 (often) to 5 (all the time) and are summed to get a total score. The minimum score possible is 30 and the maximum score possible is 150. A lower score means a better outcome. |
Baseline, End of Treatment (Week 18)
|
|
Dermatology Life Quality Index Score
時間枠:Baseline, End of Treatment (Week 18)
|
The Dermatology Life Quality Index was developed as a general quality of life instrument to measure the impact of chronic skin disease on patients. The aim of the questionnaire is to measure how much the participant's skin problems affected their life over the past week. The questionnaire contains 10 questions with responses ranging from 0 (not at all), 1 (a little), 2 (a lot) to 3 (very much) that are summed to get a total score. The minimum score possible is 0 and the maximum score possible is 30. A lower score means a better outcome. |
Baseline, End of Treatment (Week 18)
|
協力者と研究者
スポンサー
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (実際)
研究の完了 (実際)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。